Ascendis Pharma(ASND) - 2023 Q4 - Annual Report

Exhibit 99.1 PRESS RELEASE Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results – Launch of TransConTM PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024 – TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024 – Total Q4 revenue of €138 million including SKYTROFA® revenue of €64 million; Q4 operating expenses of €155 million – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, February 7, 2024 (GLOBE NEWSWIRE) – Asc ...